Originally published by our sister publication Clinical Oncology News
By Kate O’Rourke
In patients with inoperable or metastatic hormone receptor–positive (HR-positive), HER2-negative breast cancer who had received previous chemotherapy and were resistant to endocrine therapy, the antibody–drug conjugate datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo) improved progression-free survival (PFS) by two months compared with chemotherapy. This news comes from the TROPION-Breast01